https://padlet.com/uroojmorris/926qowyyuyzo Targeting mitochondrial oxidation phosphorylation eradicates therapy-resistant chronic myeloid leukaemia stem cell. en-us 2017-11-28 14:39:49 UTC 2024-05-27 12:46:07 UTC hello@padlet.com uroojmorris https://padlet.com/uroojmorris/926qowyyuyzo/wish/210927095 Kuntz, EM, 2017. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nature Medicine, [Online]. 23, 1234-1240. Available at: https://www.nature.com/articles/nm.4399 [Accessed 27 November 2017].
Improvements of this article:
Have clear sections for each part of the report.
Have more paitents to test this on as only 4 CML patients were used.

]]> 2017-11-28 14:52:42 UTC https://padlet.com/uroojmorris/926qowyyuyzo/wish/210927095 uroojmorris https://padlet.com/uroojmorris/926qowyyuyzo/wish/210936958 The aim of the research article is to investigate if targeting mitochondrial oxidation phosphorylation eradicates therapy-resistant chronic myeloid leukaemia stem cells.]]> 2017-11-28 15:06:07 UTC https://padlet.com/uroojmorris/926qowyyuyzo/wish/210936958 uroojmorris https://padlet.com/uroojmorris/926qowyyuyzo/wish/210939059 Liquid chromatography-mass spec was used to metabolically profile CD34+ and CD34- by the steady state of metabolites central to glucose, nucleotide, amino acid, fatty acid, and energy metabolism. This was done because stem cells can exhibit opposite/ corresponding traits. 
Mice were also used to study the invivo engraftment of CD34+ CML cells.]]> 2017-11-28 15:08:53 UTC https://padlet.com/uroojmorris/926qowyyuyzo/wish/210939059 uroojmorris https://padlet.com/uroojmorris/926qowyyuyzo/wish/210941876 Figure 1a,b show that the imatinib treatment targets differentiated CD34- CML cells for apoptosis, leading to enrichment of primative CD34+.
Figure 1c,d. Show that imatinib in line with resistence of CML stem cells to tyrosine kinase inhibitors treatment, colony-forming capacity of CD34+ cells is not affected. ]]> 2017-11-28 15:12:37 UTC https://padlet.com/uroojmorris/926qowyyuyzo/wish/210941876 uroojmorris https://padlet.com/uroojmorris/926qowyyuyzo/wish/210942755 Primitive CML cells rely on upregulated metabolism for their survival as they are highly susceptible to inhibition of oxidative phosphorylation, whereas normal CD34+ are not.  Also the combination treatment of imatinib and tigecycline (antibody that inbibits mitochondrial protein translation) eradicates  CML LSCs.  ]]> 2017-11-28 15:13:48 UTC https://padlet.com/uroojmorris/926qowyyuyzo/wish/210942755 uroojmorris https://padlet.com/uroojmorris/926qowyyuyzo/wish/210943305 In culture, proliferating untreated CD34+ chronic myeloid leukaemia cells rapidly lose surface CD34 expansion. Imatinib treatment primarily targets the differentiated CD34- CML cells for apoptosis, therefore leading to enrichment of more primitive CD34+ cells. ]]> 2017-11-28 15:14:35 UTC https://padlet.com/uroojmorris/926qowyyuyzo/wish/210943305